Studies, such as the STEP 4 trial, have shown that while some individuals achieve substantial weight reduction, others may see more modest results due to a combination of factors, including baseline metabolic health, lifestyle habits, and adherence to dietary recommendations
Last Published 06.01.2026 Effective Date: 06.01.2026 This policy addresses the use of intravenous enzyme replacement drug products for the treatment of Gaucher disease, including Cerezyme (imiglucerase), Elelyso (taliglucerase), and VPRIV (velaglucerase)
For the determination of TC content, after protein precipitation, 100 L of 1 MKOH in methanol was added to hydrolyze acylcarnitines
Even with advanced body composition tools such as DXA or professional BIA, lean mass is not always synonymous with skeletal muscle
In the consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology (AACE/ACE), GLP-1 RA is recommended as monotherapy in individuals with HbA1c 1% and weight reduction 3% e Compared to placebo f Compared to other incretin mimetics g Compared to exenatide and liraglutide h Compared to other therapies i Compared to comparator drugs j Compared to exenatide formulations and albiglutide Body Weight and Composition GLP-1 RA decreases gastrointestinal motility and hence increases the time for nutrient absorption
Urbina PhD 2 , Flor Lpez MSc 2 , Frank Hernndez Rosales PhD 1 1 Ozone Research Center, National Center for Scientific Research
